On this page
- TL;DR
- Seborrheic dermatitis VA rating criteria (DC 7806)
- Topical versus systemic therapy for a VA skin rating
- The seborrheic dermatitis C&P exam
- Seborrheic dermatitis rated as disfigurement or scars
- How to prove seborrheic dermatitis is service connected
- Why VA denies seborrheic dermatitis claims
- Questions veterans ask about seborrheic dermatitis
- Bottom Line
Seborrheic dermatitis commonly affects the scalp, the central face, including the folds beside the nose, and the upper chest. For VA purposes, it is generally evaluated as dermatitis or eczema under Diagnostic Code 7806 in 38 CFR § 4.118.
The General Rating Formula for the Skin offers two main paths: how much of the entire body or exposed areas the characteristic lesions cover, and how long qualifying systemic therapy was required during the prior 12 months. Because the face counts as an exposed area, a relatively small total-body footprint can still matter. If disfigurement or scars are the predominant disability, the schedule permits a different rating path.
The biggest evidence problem is timing. Seborrheic dermatitis is a chronic condition that flares and improves. A clear exam day can understate the condition unless the record preserves photographs, treatment history, and clinician estimates from active periods.
This page covers the seborrheic dermatitis rating criteria, topical versus systemic therapy, the C&P exam, rating as disfigurement or scars, how to prove service connection, and why VA denies these claims.
TL;DR
- Seborrheic dermatitis is generally rated under DC 7806 and the General Rating Formula for the Skin.
- 0%: less than 5 percent of the body and exposed areas, with no more than topical therapy during the past 12 months.
- 10%: 5 to less than 20 percent of the body or exposed areas, or systemic therapy for less than six weeks during the prior 12 months.
- 30%: 20 to 40 percent of the body or exposed areas, or systemic therapy for six weeks or more but not constantly.
- 60%: more than 40 percent of the body or exposed areas, or constant or near-constant systemic therapy.
- Under § 4.118(a), systemic therapy is treatment administered by a route other than the skin. Topical therapy is treatment administered through the skin.
- The schedule also permits evaluation as disfigurement of the head, face, or neck or as scars when that is the predominant disability.
- Stress has been linked to flares, but it does not create an automatic secondary link to PTSD or anxiety.
- Across 604 decided Board rulings on seborrheic dermatitis from 2021 to 2026, 19.9% were granted, 33.4% denied and 46.7% remanded. The Board section below breaks those rulings down.
Seborrheic dermatitis VA rating criteria (DC 7806)
The current skin formula provides these levels.
- 0%: characteristic lesions involving less than 5 percent of the entire body and less than 5 percent of exposed areas, with no more than topical therapy required during the past 12 months.
- 10%: lesions involving at least 5 but less than 20 percent of the entire body or exposed areas, or intermittent systemic therapy for a total duration of less than six weeks during the prior 12 months.
- 30%: lesions involving 20 to 40 percent of the entire body or exposed areas, or systemic therapy for six weeks or more but not constantly during the prior 12 months.
- 60%: lesions involving more than 40 percent of the entire body or exposed areas, or constant or near-constant systemic therapy during the prior 12 months.
The body-area and treatment paths are alternatives. A veteran can meet a level through either. The regulation lists the two 0 percent area measures with "or," but reaching 5 percent on either measure already meets the 10 percent level, so in practice 0 percent means both measures stay under 5 percent and treatment was topical only. The percentage is not based on itch, flakes, embarrassment, or treatment difficulty by themselves, though those facts can explain functional impact and flare history.
Topical versus systemic therapy for a VA skin rating
Section 4.118(a) defines the distinction by route.
- Systemic therapy is administered by a route other than the skin, such as orally, by injection, suppository, or intranasally.
- Topical therapy is administered through the skin.
That current definition prevents a common error: assuming a topical corticosteroid is systemic merely because corticosteroids can be systemic drugs in other forms. In Johnson v. Shulkin, 862 F.3d 1351 (Fed. Cir. 2017), the Federal Circuit rejected the reading that any use of a topical corticosteroid is systemic therapy under DC 7806, and VA wrote the route definition into the skin rules effective August 13, 2018. The treatment record should identify the medication, route, start and stop dates, frequency, and the skin condition it treated.
The formula lists examples such as corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, and other immunosuppressive drugs, but the route and duration still need to match the current rule.
Standard treatment for seborrheic dermatitis relies mainly on antifungals, topical corticosteroids and calcineurin inhibitors. Applied to the skin, including as a medicated shampoo, those are topical therapy for VA purposes. Oral isotretinoin, a retinoid that has been studied for moderate to severe seborrheic dermatitis, is systemic therapy by route.
The seborrheic dermatitis C&P exam
The C&P examiner should estimate both the entire-body percentage and the exposed-area percentage. VA's Skin Diseases Disability Benefits Questionnaire (DBQ) asks for the exposed area as the face, neck and hands. Because exposed area is an independent route, facial involvement should not disappear inside a small total-body number. Scalp involvement counts toward the entire-body figure; the scalp is not on the form's list of exposed areas.
The examiner should document these points.
- every affected location;
- percentage of the entire body and exposed areas;
- lesion appearance and any disfigurement or scar features;
- all treatments during the prior 12 months, including route and total duration;
- flare frequency, duration, triggers, and severity;
- whether the exam occurs during an active phase; and
- work or daily-function effects.
If the condition is inactive that day, ask that the report acknowledge the history and the submitted flare evidence. Photographs and contemporaneous dermatology records can bridge the snapshot gap. Useful evidence from a flare includes the following.
- dated photographs from consistent angles and lighting;
- dermatology notes describing each affected region;
- clinician estimates of total and exposed area;
- records of scaling, redness, crusting, or inflammation;
- prescription and refill history; and
- a calendar showing flare duration and treatment.
Veterans can describe locations and duration, but a clinician's percentage estimate is stronger than a self-calculated body-surface number. The C&P exam prep tool can help you organize that history before the exam.
Seborrheic dermatitis rated as disfigurement or scars
The General Rating Formula permits evaluation under DC 7800 for disfigurement of the head, face, or neck, or under the scar codes, depending on the predominant disability. This is an alternative evaluation path, not permission to count the same lesion effects twice.
When persistent facial changes, tissue characteristics, painful scarring, or unstable scars are present, the examination should document those features. See the scars page for the separate criteria. 38 CFR § 4.14 still prohibits duplicating the same manifestation under multiple codes.
How to prove seborrheic dermatitis is service connected
Direct service connection. In-service treatment, photographs, shaving profiles, medical visits for scalp or facial symptoms, and credible statements can establish onset. A current diagnosis and a medical link to that history complete the path under § 3.303.
Continuity evidence. Because the condition waxes and wanes, gaps in formal treatment do not necessarily mean symptoms stopped. Statements, photos, over-the-counter purchase records, and primary-care notes can help document the course, while the medical nexus addresses whether it is the same chronic condition.
Secondary aggravation. Stress is a recognized flare factor: in a 2020 study of patients seen by a dermatologist, a higher level of stress in the past month was linked to flares. That does not prove PTSD or anxiety caused the skin disease. A claim under 38 CFR § 3.310(b) needs a clinician's opinion that your seborrheic dermatitis is aggravated by your service-connected condition, meaning it would be less severe but for that condition, plus medical evidence of baseline severity and of the measurable worsening attributable to the service-connected condition.
Why VA denies seborrheic dermatitis claims
Seborrheic dermatitis claims do a little worse at the Board than the average claim. Across 604 decided Board rulings on seborrheic dermatitis from 2021 to 2026, 19.9% were granted, 33.4% denied and 46.7% remanded. That grant rate is 4.8 points below the Board-wide 24.7 percent.
When the Board denied service connection for seborrheic dermatitis, the missing piece was the medical link to service, not the diagnosis or the in-service history. The rating side has its own failure points. These patterns repeat.
No medical link to service. The service records show scalp or facial treatment, but no opinion explains why the current seborrheic dermatitis is the same condition rather than a later onset.
Only the scalp is counted. Facial, chest, or other involved areas never make it into the DBQ.
Exposed area is omitted. The examiner reports total body percentage but not the separate exposed-area percentage.
Topical treatment is called systemic. The route definition in § 4.118(a) is ignored.
Treatment duration is vague. The record lists medications but not how many weeks they were used during the relevant 12 months.
A clear-day exam controls. The file contains no dated flare photographs or active-phase treatment notes.
Stress is treated as an automatic link. The medical evidence does not establish causation or aggravation by a service-connected condition. On the other side, a VA opinion that says only "not caused by" and never addresses whether the service-connected condition made the skin disease worse is inadequate (El-Amin v. Shinseki, 26 Vet. App. 136 (2013)).
When the Board sends a seborrheic dermatitis claim back instead of deciding it, the most common reason is an inadequate VA exam or opinion, followed by records VA still had to get. The Board section below shows the remand reasons, results by what the appeal asked for, and how claims argued as direct, secondary and presumptive have fared.
Questions veterans ask about seborrheic dermatitis
Is seborrheic dermatitis a VA disability?
Yes, when it is service connected. VA rates it under DC 7806, dermatitis or eczema, with the General Rating Formula for the Skin, from 0 to 60 percent. You need a current diagnosis, evidence of onset or treatment in service, and a medical link between the two.
What is the highest VA rating for seborrheic dermatitis?
60 percent under the skin formula, for lesions on more than 40 percent of the entire body or exposed areas, or constant or near-constant systemic therapy over the past 12 months. If disfigurement of the head, face or neck is the predominant disability, VA can rate it under DC 7800 instead, which goes up to 80 percent.
Does a topical steroid count as systemic therapy for a VA skin rating?
No. Under 38 CFR § 4.118(a), treatment applied through the skin is topical therapy, including a steroid cream, lotion or medicated shampoo. Only treatment given by another route, such as by mouth or by injection, counts toward the systemic-therapy levels.
Can seborrheic dermatitis be secondary to PTSD?
It can, but only with a medical opinion about your case. Because stress is a recognized flare factor, the usual theory is aggravation: that your service-connected PTSD made the skin disease worse than it would otherwise be. Under § 3.310(b), VA also needs medical evidence of how severe the skin disease was before that worsening.
Can VA rate seborrheic dermatitis and another skin condition separately?
Only when they involve separate areas of skin. Under 38 CFR § 4.118(b), if two skin conditions affect the same area, VA uses only the highest evaluation. Seborrheic dermatitis on the face and eczema on the legs can be rated separately and combined; two conditions on the same patch of scalp cannot.
Bottom Line
Seborrheic dermatitis is generally a DC 7806 claim. The rating depends on the higher qualifying path between body or exposed-area coverage and systemic-treatment duration. Preserve active-flare evidence, document every treated area, distinguish topical from systemic therapy by route, and consider the disfigurement or scar formula only when that is the predominant disability.
Methodology and Limitations
- Authorities checked: 38 CFR §§ 3.303, 3.310, 4.14, and 4.118, including § 4.118(a) and (b), the General Rating Formula for the Skin, DC 7800, and DC 7806, checked on October 6, 2026 against the eCFR text current on October 1, 2026. The topical and systemic distinction was also checked against VA's 2018 skin rule (83 FR 32592, effective August 13, 2018), which discusses Johnson v. Shulkin. The exposed-area definition comes from VA's Skin Diseases DBQ (updated July 15, 2024).
- Medical sources: Navarro Triviño et al., "Seborrheic Dermatitis Revisited," Biomedicines (2025); Schwartz et al., "Seborrheic dermatitis: an overview," American Family Physician (2006); Lancar et al., "Risk Factors for Seborrhoeic Dermatitis Flares," Acta Dermato-Venereologica (2020); and Alsayoud et al., a systematic review of isotretinoin for seborrheic dermatitis, Clinical, Cosmetic and Investigational Dermatology (2025), each read as a PubMed abstract. Treatment decisions belong to a clinician.
- Board statistics: Claim Raven's read of 510,968 Board decisions from 2021 to 2026, which contain 1,376,193 rulings. Of 658 Board rulings on seborrheic dermatitis, 604 were decided; dismissed, withdrawn and moot rulings are excluded from the shares, and the Board section below is computed from the same data.
- Limitations: Body-area estimates and treatment classification depend on the medical record. This page explains the schedule and does not estimate an individual percentage.
